{
    "nct_id": "NCT04835805",
    "official_title": "A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy",
    "inclusion_criteria": "* ECOG Performance Status of 0 or 1\n* Histologically confirmed, metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III) cutaneous melanoma, that has progressed on or after treatment with anti-PD-1 or anti-PD-L1 therapy. Patients may have received up to two lines of systemic cancer therapy. Treatment with anti-PD-1/PD-L1 in the adjuvant setting is acceptable. Patients must have progressed disease at study entry\n* Documentation of NRAS mutation-positive within 5 years prior to screening\n* Tumor specimen availability\n* Adequate hematologic and end-organ function\n* Measurable disease per RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a pan-RAF inhibitor\n* Treatment with systemic immunotherapy agents (e.g., anti-CTLA4, anti-PD(L)1, cytokine therapy, investigational therapy, etc.) within 28 days prior to C1D1\n* Symptomatic, untreated, or actively progressing CNS metastases\n* History or signs/symptoms of clinically significant cardiovascular disease\n* Known clinically significant liver disease\n* History of autoimmune disease or immune deficiency\n* Prior treatment with a MEK inhibitor (cobimetinib arm)\n* History of or evidence of retinal pathology on ophthalmologic examination (cobimetinib arm)\n* History of immune-related AE attributed to prior anti-PD(L)1 therapy that resulted in permanent discontinuation of anti-PD(L)1 therapy (nivolumab arm)",
    "miscellaneous_criteria": ""
}